MNG974
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.456
- PANCREAS_BETA_CELLS+0.377
- KRAS_SIGNALING_DN+0.280
- INFLAMMATORY_RESPONSE+0.269
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
- ALLOGRAFT_REJECTION+0.191
- KRAS_SIGNALING_UP+0.124
- HEDGEHOG_SIGNALING+0.121
- ESTROGEN_RESPONSE_EARLY+0.083
- IL6_JAK_STAT3_SIGNALING+0.058
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.554
- DNA_REPAIR-0.510
- INTERFERON_ALPHA_RESPONSE-0.500
- MYC_TARGETS_V1-0.408
- CHOLESTEROL_HOMEOSTASIS-0.384
- FATTY_ACID_METABOLISM-0.372
- PEROXISOME-0.368
- E2F_TARGETS-0.355
- ADIPOGENESIS-0.320
- MYC_TARGETS_V2-0.293
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1334440 | GTEX | — | 0.878 |
| 2 | SRR1416410 | GTEX | — | 0.877 |
| 3 | SRR13311184 | — | — | 0.872 |
| 4 | SRR1443979 | GTEX | — | 0.871 |
| 5 | R415 | — | — | 0.871 |
| 6 | MNG1152 | — | — | 0.870 |
| 7 | BS_MQCKXD60 | Glial-neuronal tumor NOS | — | 0.866 |
| 8 | SRR1440246 | GTEX | — | 0.865 |
| 9 | MNG1135 | — | — | 0.863 |
| 10 | SRR1316624 | GTEX | — | 0.859 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.456 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.377 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.269 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.191 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.124 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.121 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.083 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.058 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.041 | Idelalisib | — uncovered |
| COAGULATION | 0.033 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.021 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.019 | Inavolisib | — uncovered |
| MYOGENESIS | 0.016 | Inavolisib | — uncovered |